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Abstract Prenatal exposure to antiepileptic drugs (AEDs)
increases the risk of major congenital malformations
(MCM) in the fetus. AED-related abnormalities include
heart and neural tube defects, cleft palate, and urogenital
abnormalities. Among the various congenital anomalies of
the kidney and urinary tract (CAKUT), multicystic dys-
plastic kidney (MCDK) disease is one of the most severe
expressions. Although prenatal ultrasound (US) examina-
tion has increased the prenatal diagnosis of MCDK, the
pathogenesis is still unclear. We report on four cases of
MCDK in infants of epileptic women treated with AEDs
during pregnancy. From October 2003 to June 2006, we
observed four infants with unilateral MCDK born to
epileptic women. Three patients were considered to have
typical features of multicystic dysplastic kidney, and one
infant was operated because of a cystic pelvic mass in the
absence of a kidney in the left flank. The macroscopic
appearance of this mass showed an ectopic multicystic
kidney confirmed by histological findings. All patients have
been studied by US scans, voiding cystourethrogram
(VCUG), and radionuclide screening isotope imaging. The
prenatal exposure to AEDs increases the risk of major
congenital malformations from the background risk of 1–
2% to 4–9%. AEDs may determine a defect in apoptosis
regulation that could lead to abnormal nephrogenesis,
causing MCDK. Carbamazepine (CBZ) and phenobarbital
(PHB) during pregnancy should be used at the lowest
dosage compatible with maternal disease. The reduction, or
even suspension, of drug dosage should be achieved from
the periconceptional period to the first 8 weeks of gestation
to avoid any interference with organogenesis.
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Introduction
It is widely accepted that prenatal exposure to antiepileptic
drugs (AEDs) increases the risk of major congenital
malformations (MCM) in the fetus [1]. AED-related
abnormalities include congenital midline heart defects,
neural tube defects, cleft lip and palate, polydactyly, and
urogenital abnormalities (hypospadia, duplex system, renal
dysplasia, hydronephrosis) [2]. There is no evidence that
infants born to untreated women with a history of epilepsy
have an increased risk of MCM [3]. On the other hand,
suspension of antiepileptic therapy may cause strong
concern that the mother’s seizures themselves could have
a harmful effect on the fetus, including fetal bradycardia
and mechanical consequences of maternal traumas [4].
Among the various congenital anomalies of the kidney and
urinary tract (CAKUT), multicystic dysplastic kidney
(MCDK) is one of the most severe expressions. Many
teratogenic effects of AEDs are well described, but MCDK
has not been reported in the literature. Although prenatal
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ultrasound (US) examination has increased the diagnosis of
MCDK, the pathogenesis is still unclear. We report on four
cases of unilateral MCDK in infants of epileptic women
treated with AEDs during pregnancy.
Patient reports
Our Institution is a level III referral center for high-risk
pregnancies and newborns with congenital malformations
in western Sicily. A mean of 950 prenatal US screenings are
performed every year, with a mean of 40 US investigations
per year in epileptic women. The incidence of isolated
MCDK in western Sicily is 1.17/10.000 births [Indagine
Siciliana Malformazioni Congenite (ISMAC) register for
congenital malformations 2000–2005, personal data, not
published]. In the last 36 months, we observed eight infants
with unilateral MCDK. Four infants were born to epileptic
women who underwent antiepileptic treatment with carba-
mazepine (CBZ) and phenobarbital (PHB) during pregnan-
cy, and MCDK was diagnosed in utero with routine US
scans. Amniocentesis, performed within 21 weeks of
gestation, showed a normal karyotype in all patients.
All mothers started folic acid administration (5 mg per
day) 1 month before pregnancy. No other risk factors such
as smoking, alcohol, drugs, infections [toxoplasmosis, other
agents, rubella, cytomegalovirus, and herpes simplex
(TORCH)], abortions, hypertension, gestosis, diabetes, or
other pharmacological treatments were present. For all
women, the average daily dose of CBZ and PHB was
650 mg and 130 mg, respectively. Dose adjustment was
made on a clinical basis to achieve the lowest dosage,
especially during the first trimester of gestation. Three
mothers underwent an elective cesarean section because of
other reasons not related to epilepsy; one mother underwent
urgent cesarean section because of evidence of fetal
decelerations.
All newborns were delivered at term and had a birth
weight appropriate for gestational age. Clinical findings
showed facial dysmorphic features as reported in Table 1.
Three patients showed typical US scan features of MCDK
and, therefore, we chose a nonoperative approach with
clinical and US follow-up monitoring. One infant was
operated because of computed tomography (CT) evidence
of a cystic pelvic mass in absence of kidney in the left
flank. The macroscopic appearance showed an ectopic
multicystic kidney confirmed by histological findings.
At birth, no newborns showed any AED intoxication,
drowsiness, excitement, or insufficient milk intake. The
Finnegan Score was normal. Cerebral, cardiac, and abdom-
inal US scans were unremarkable. The studies at birth
included voiding cystourethrogram (VCUG) showing a
contralateral vesicoureteral reflux only in one patient. Renal
US scans of all parents were negative. At 1 month of age,
radionuclide screening isotope imaging provided the ab-
sence of function in the multicystic kidney, and abdominal
US scans showed compensatory hypertrophy of the
contralateral healthy kidney. At clinical follow-up, growth
rates and neurobehavioral assessment were within the
normal limits. Reabsorption of the cysts was noted in two
patients, whereas the cystic content did not change at 1-year
follow-up in one patient.
Discussion
Women with epilepsy account for approximately 0.6% of
all pregnancies [5]. There are approximately 1.1 million
women of childbearing age in the United States with
epilepsy [6]. The maternal use of AEDs during pregnancy
is based on the assumption that seizures, especially first-
trimester seizures, place mother and fetus at risk of
hypoxia, acidosis, and injury from blunt trauma being more
harmful than the drugs [7]. Unfortunately, the prenatal
exposure to AEDs increases the risk of a MCM from the
background risk of 1–2% to 4–9% [8]. The risk of
congenital malformations has been associated with all the
AEDs, but recent studies suggest differences in teratogenic
effects between various AEDs. The teratogenic effect of
valproic acid (VPA) has been well established, MCM
Table 1 Clinical findings and 1-year follow-up in four infants
Case no. Birth weight (g) and
gestational age (wk)
Dysmorphic features Renal features One-year follow-up
1 28.00 Hypertelorism Left multicystic dysplastic kidney Cystic reabsorption
37.5
2 33.20 Hypertelorism, epicanthal folds,
short nose with long filtrum
Left multicystic dysplastic kidney Cysts did not change
38.2
3 31.60 Hypertelorism, epicanthal folds Right multicystic dysplastic kidney Cystic reabsorption
38.0
4 25.90 Epicanthal folds, prominent lips Absence of the kidney in the left flank;
ectopic multicystic kidney
Surgery intervention at birth
37.2
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incidence being increased ten-fold in the offspring of VPA-
treated pregnant women [9]. Therefore, CBZ and PHB
represented the drugs of choice for the treatment of
virtually all types of epilepsy in the last decade. Neverthe-
less, Matalon et al. [10] found that CBZ exposure during
pregnancy increases the risk of MCM from 2.7% to 6.7%.
Furthermore, a combination of CBZ with PHB is more
teratogenic than CBZ therapy alone [11].
It has been supposed that a direct toxic action of reactive
epoxides or free radicals start oxidative stress. Lindhout et
al. [12] proposed a reduced activity of epoxide hydrolase,
which is involved in the detoxification of epoxides
produced in CBZ catabolism. There could be genetic
differences in the prevalence of people with low activity
of epoxide hydrolase, which may explain the different rates
of CBZ-induced congenital anomalies. Among urogenital
defects, the association between AED therapy during
pregnancy and hypospadia has been reported [13]. There
is less evidence about kidney involvement (hydronephrosis,
renal dysplasia) [14] and prenatal AED exposure.
The pathway of AED damage on the developing kidney
is not completely understood. Several hypotheses have
been proposed regarding the ontogenesis of various forms
of CAKUT. A well-orchestrated program of cellular
proliferation, differentiation, and apoptosis has been dem-
onstrated to be an essential component of normal kidney
and urinary-tract embryonic development [15]. Different
active signals (pax-2, bcl-2) are thought to promote
nephrogenesis and induce renal dysplasia. Bcl-2 is a protein
normally expressed in developing kidney that protects cells
from apoptotic death [16]. In transgenic mice, an over-
expression of bcl-2 leads to renal cystogenesis through a
high apoptotic rate [17]. Homozygous null bcl-2 mice
develop renal cysts by increased apoptosis of metanephric
blastema during embryonic kidney development [18].
Therefore, in bcl-2 knockout mice, cystic renal formation
may result from an inability of some renal cells to undergo
terminal differentiation. Winyard et al. [19] demonstrated
that apoptosis is prominent in undifferentiated cells around
dysplastic tubules; on the other hand, apoptosis is rare in
dysplastic epithelia, which are thought to be ureteric bud
malformations. Bcl-2 is consistently and ectopically
expressed in dysplastic kidney epithelia. All these data
suggest that cystic formation can be modulated by bcl-2
overexpression or can result from a reduced ability of renal
cells to achieve terminal differentiation. It has been shown
that PHB increases bcl-2 levels, leading to consistent
reduction or suppression of programmed cell death [20,
21]. PHB therapy during pregnancy could lead to abnormal
nephrogenesis causing MCDK through an abnormal regu-
lation of bcl-2.
Questions still remain as to whether bcl-2 involvement
may explain the clinical observations of MCDK after
prenatal exposure to AEDs; nevertheless, apoptosis dereg-
ulation probably plays a role in the multifactorial processes
that lead to MCDK. Even if the AED mechanism involved
in renal dysplasia remains unclear, our clinical findings
suggest an AED toxicity during prenatal development, an
observation supported by typical dysmorphic features at
birth. It is difficult to demonstrate a causal effect between
an infant’s MCM and AEDs exposure during pregnancy.
We believe that the list of malformations associated with
the use of AEDs is probably incomplete, because most
studies did not detect uncommon defects. To our knowl-
edge, this is the first report of MCDK associated with CBZ
and PHB maternal exposure.
Epileptic women of childbearing age must be informed
about the risks of anticonvulsant consumption during preg-
nancy, especially in the periconceptional period. Epileptic
women who undergo a programmed pregnancy may reduce
the teratogenic risk by the use of folate prior to conception
and the use of AEDs in monotherapy, keeping dosage as low
as possible during organogenesis. Although we still need
more evidences to assess the precise risk of MCDK after
antiepileptic treatment during pregnancy, we assume that in
selected women, the ideal management may be to lower AED
dosage prior to conception and possibly to suspend adminis-
tration at least during the first 8 weeks of gestation in order to
avoid any interference with organogenesis.
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